Mimedx (MDXG) Cash & Equivalents (2010 - 2026)

Mimedx has disclosed Cash & Equivalents across 17 years of filings, most recently posting $159.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $159.8 million, up 50.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $159.8 million (up 50.12% YoY), and the FY2025 annual result was $166.1 million, up 59.1% from the prior year.
• Cash & Equivalents came in at $159.8 million for Q1 2026 at Mimedx, down from $166.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $166.1 million in Q4 2025 to a low of $48.5 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $78.8 million (2022), against an average of $94.0 million.
• Across the five-year window, Cash & Equivalents declined 24.27% in 2022 and soared 119.5% in 2025, its largest moves.
• Mimedx's Cash & Equivalents stood at $66.0 million in 2022, then increased by 24.34% to $82.0 million in 2023, then climbed by 27.34% to $104.4 million in 2024, then jumped by 59.1% to $166.1 million in 2025, then decreased by 3.82% to $159.8 million in 2026.
• The last three Cash & Equivalents figures came in at $159.8 million (Q1 2026), $166.1 million (Q4 2025), and $142.1 million (Q3 2025), per Business Quant data.